Cytogenetic damage induced by radiotherapy. Evaluation of protection by amifostine and analysis of chromosome aberrations persistence

International Journal of Radiation Biology

Volumn 84, Issue 3, 2008, Pages 243-251

  Xunclà, Mar ^a   Barquinero, Joan Francesc ^a   Caballín, María Rosa ^a   Craven Bartle, Jordi ^b   Ribas, Montserrat ^b   De Vega, José Manuel ^b   Barrios, Leonardo ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Amifostine; Persistence of chromosome aberrations; Radiotherapy

Indexed keywords

AMIFOSTINE;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER RADIOTHERAPY; CHROMOSOME ABERRATION; CHROMOSOME DAMAGE; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; CORRELATION ANALYSIS; DICENTRIC CHROMOSOME; DRUG EFFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; EVALUATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTECTION; RADIATION HAZARD;

AMIFOSTINE; CHROMOSOME ABERRATIONS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOCYTES; MALE; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS;

EID: 40049109356     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.1080/09553000801902141     Document Type: Article

References (42)

1. Anne PR, Machtay M, Rosenthal DI, Brizel DM, Morrison WH, Irwin DH, Chougule PB, Estopinal NC, Berson A, Curran WJ Jr. 2007. A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer. International Journal of Radiation Oncology Biology Physics 67:445-452.
2. Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N. 2002. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. International Journal of Radiation Oncology Biology Physics 52:739-747.
3. Barrios L, Caballín MR, Miró R, Fuster C, Guedea F, Subias A, Egozcue J. 1990. Cytogenetic effects of radiotherapy: frequency and types of chromosome aberrations. International Journal of Radiation Oncology Biology Physics 19:371-375.
4. Barquinero JF, Barrios L, Caballín MR, Miró R. Ribas M. Subias A. Egozcue J. 1993. Cytogenetic análisis of lymphocytes from hospital workers occupationally exponed to low levels of ionizing radiation. Mutation Research 286:275-279.
5. Barquinero JF, Barrios L, Caballín MR, Miró R, Ribas M, Egozcue J. 1997. Biological dosimetry in simulated in vitro partial irradiations. International Journal of Radiation Biology 71:435-440.
6. Bauchinger M, Blakely WF, Darroudi F, Edwards A, Fenech M, Hayata I, Köteles GJ, Lindholm C, Lloyd DC et al. 2001. Cytogenetic analysis for radiation dose assessment. A manual. IAEA Technical Reports Series no. 405, Vienna.
7. Calabro-Jones PM, Aguilera JA, Ward JF, Smoluk GD, Fahey RC. 1988. Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Research 48:3634-3640.
8. Capizzi RL, Scheffler BJ, Schein PS. 1993. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy. Cancer 72:3495-3501.
9. Cigarrán S, Barquinero JF, Barrios L, Ribas M, Egozcue J, Caballón MR. 2001. Cytogenetic analyses by fluorescence in situ hybridization (FISH) in hospital workers occupationally exposed to low levels of ionizing radiation. Radiation Research 155:417-423.
10. 131I-Lipiodol therapy in patients with hepatocellular carcinoma. Journal of Nuclear Medicine 45:612-618.
11. Dunst J, Semlin S, Pigorsch S, Muller AC, Reese T. 2000. Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients. Strahlentherapie und Onkologie 176:416-421.
12. Duran A, Barquinero JF, Caballín MR, Ribas M, Puig P, Egozcue J, Barrios L. 2002. Suitability of FISH painting techniques for the detection of partial-body irradiations for biological dosimetry. Radiation Research 157:461-468.
13. Durante M, Yamada S, Ando K, Furusawa Y, Kawata T, Majima H, Nakano T, Tsujii H. 1999. Measurements of the equivalent whole-body dose during radiation therapy by cytogenetic methods. Physics in Medicine and Biology 44:1289-1298.
14. Edwards AA, Lindholm C, Darroudi F, Stephan G, Romm H, Barquinero JF, Barrios L, Caballín MR, Roy L, Whitehouse CA, Tawn EJ, Moquet J, Lloyd DC, Voisin P. 2005. Review of translocations detected by FISH for retrospective biological dosimetry applications. Radiation Protection Dosimetry 113:396-402.
15. Finnon P, Lloyd DC, Edwards AA. 1995. Fluorescence in situ hybridization detection of chromosomal aberrations in human lymphocytes: Applicability to biological dosimetry. International Journal of Radiation Biology 68:429-435.
16. Gebhart E, Neubauer S, Schmitt G, Birkenhake S, Dunst J. 1996. Use of a three-color chromosome in situ suppression technique for the detection of past radiation exposure. Radiation Research 145:47-52.
17. Guerrero-Carbajal YC, Moquet JE, Edwards AA, Lloyd DC. 1998. The persistence of FISH translocations for retrospective biological dosimetry after stimulated whole or partial body irradiation. Radiation Protection Dosimetry 76:159-168.
18. Huber R, Braselmann H, Kulka U, Schumacher-Georgiadou V, Bayerl A, Molls M, Bauchinger M. 1999. Follow-up analysis of translocation and dicentric frequencies, measured by FISH-chromosome painting in breast cancer patients after partial-body radiotherapy with little bone marrow exposure. Mutation Research 446:103-109.
19. Inano H, Onoda M, Suzuki K, Kobayashi H, Wakabayashi K. 2000. Inhibitory effects of WR-2721 and cysteamine on tumor initiation in mammary glands of pregnant rats by radiation. Radiation Research 153:68-74.
20. Knehr S, Zitzelsberger H, Bauchinger M. 1998. FISH-based analysis of radiation-induced chromosomal aberrations using different nomenclature systems. International Journal of Radiation Biology 73:135-141.
21. Koukourakis MI, Ktenidou-Kartali S, Bourikas G, Kartalis G, Tsatalas C. 2003. Amifostine protects lymphocytes during radiotherapy and stimulates expansion of the CD95/Fas and CD31 expressing T-cells, in breast cancer patients. Cancer Immunology Immunotherapy 52:127-131.
22. Kuechler A, Dreidax M, Pigorsh SU, Liher T, Claussen U, Wendt TG, Dunst J. 2003. Residual chromosomal damage after radiochemotherapy with and without amifostine detected by 24-color FISH. Strahlentherapie und Onkologie 179:493-498.
23. Lee R, Yamada S, Yamamoto N, Miyamoto T, Ando K, Durante M, Tsujii H. 2004. Chromosomal aberrations in lymphocytes of lung cancer patients treated with carbon ions. Journal of Radiation Research 45:195-199.
24. Lindholm C, Tekkel M, Veidebaum T, Ilus T, Salomaa S. 1998. Persistence of translocations after accidental exposure to ionizing radiation. International Journal of Radiation Biology 74:565-571.
25. Lindholm C, Edwards A. 2004. Long-term persistence of translocations in stable lymphocytes from victims of a radiological accident. International Journal of Radiation Biology 80:559-566.
26. Littlefield LG, Joiner EE, Colyer SP, Sallam F, Frome EL. 1993. Concentration-dependent protection against X-ray induced chromosome aberrations in human lymphocytes by the aminothiol WR-1065. Radiation Research 133:88-93.
27. Manola KN, Terzoudi GI, Dardoufas CE, Malik SI, Pantelias GE. 2003. Radioprotective effect of amifostine on cells from cancer prone patients and healthy individuals studied by G2 and PCC assays. International Journal of Radiation Biology 79:831-838.
28. Muller I, Geinitz H, Braselmann H, Baumgartner A, Fasan A, Thamm R, Molls M, Meineke V, Zitzelsberger H. 2005. Time-course of radiation-induced chromosomal aberrations in tumor patients after radiotherapy. International Journal of Radiation Oncology Biology Physics 63:1214-1220.
29. Perry P, Wolff S. 1974. New Giemsa method for differential staining of sister chromatids. Nature 261:156-158.
30. Rao CR, Chakravarti IM. 1956. Some small sample tests of significance for a Poisson distribution. Biometrics 12:264-282.
31. Rades D, Fehlauer F, Bajrovic A, Nahlmann B, Richter E, Alberti W. 2004. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiotherapy and Oncology 70:261-264.
32. Rodriguez P, Montoro A, Barquinero JF, Caballín MR, Villaescusa I, Barrios L. 2004. Analysis of translocations in stable cells and their implications in retrospective biological dosimetry. Radiation Research 162:31-38.
33. Savage JRK, Simpson P. 1994. On the scoring of FISH-"painted" chromosome-type exchange aberrations. Mutation Research 307:345-353.
34. Sevan'kaev AV, Lloyd DC, Edwards AA, Khvostunov IK, Mikhailova GF, Golub EV, Shepel NN, Nadejina NM, Galstian IA, Nugis VY, Barrios L, Caballín MR, Barquinero JF. 2005. A cytogenetic follow-up of some highly irradiated victims of the Chernobyl accident. Radiation Protection Dosimetry 113:152-161.
35. Spencer CM, Goa KL. 1995. Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs 50:1001-1031.
36. Sreedevi B, Rao BS, Nagaraj H, Pal NK. 2001. Chromosome aberration analysis in radiotherapy patients and simulated partial body exposures: biological dosimetry for non-uniform exposures. Radiation Protection Dosimetry 94:317-322.
37. Tawn EJ, Whitehouse CA. 2003. Persistence of translocation frequencies in blood lymphocytes following radiotherapy: implications for retrospective radiation biodosimetry. Journal of Radiological Protection 23:423-430.
38. Tucker JD, Morgan WF, Awa AA, Bauchinger M, Blakey D, Cornforth MN, Littlefield LG, Natarajan AT, Shasserre C. 1995. A proposed system for scoring structural aberrations detected by chromosome painting. Cytogenetics and Cell Genetics 68:211-221.
39. Venkatachalam P, Solomon FD, Prabhu BK, Mohankumar MN, Gajendiran N, Jeevanram RK. 1999. Estimation of dose in cancer patients treated with fractionated radiotherapy using translocation, dicentrics and micronuclei frequency in peripheral blood lymphocytes. Mutation Research 429:1-12.
40. Wasserman T, Mackowiak JI, Brizel DM, Oster W, Zhang J, Peeples PJ, Sauer R. 2000. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology Biology Physics 48:1035-1039.
41. Wasserman TH, Brizel DM, Henke M, Monnier A, Eschwege F, Sauer R, Strnad V. 2005. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and-neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology Biology Physics 63:985-990.
42. Yuhas JM, Storer JB. 1969. Differential chemoprotection of normal and malignant tissues. Journal of the National Cancer Institute 42:331-335.